MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by TransCode Therapeutics, Inc.

< Previous 1 2 Next >
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
TransCode Therapeutics, Inc. Announces $8 Million Private Placement
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
TransCode Therapeutics Open Letter to Shareholders
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
TransCode Therapeutics, Inc. Announces Closing of Public Offering
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
TransCode Therapeutics, Inc. Announces Pricing of Public Offering
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
TransCode Therapeutics Open Letter to Shareholders
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
TransCode Therapeutics Reports 2023 Results; Provides Business Update
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
TransCode Therapeutics Announces Closing of $7.25 Million Public Offering
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
TransCode Therapeutics Announces 1-for-40 Reverse Stock Split
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
TOP
Email a Story